Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.49 |
| ▸ | GCGR | P47871 | 7/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | IDH1 | O75874 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GIPR | P48546 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651445 | 0.83 | MRGPRX1 (0.49) | PTGER4GCGRPIN1NPC1 | |
| SCHEMBL2652463 | 0.82 | PTGER4 (0.51) | PTGER4PIN1NPC1 | |
| SCHEMBL2654491 | 0.81 | NAMPT (0.51) | PTGER4GCGRIDH1CYP3A4CYP2C9 | |
| SCHEMBL2651211 | 0.79 | GCGR (0.56) | GCGRIDH1EGLN1CYP3A4CYP2C8 | |
| SCHEMBL2661876 | 0.78 | PTGER4 (0.51) | PTGER4GCGRPIN1 | |
| SCHEMBL2653392 | 0.78 | GCGR (0.48) | GCGRIDH1EGLN1CYP3A4CYP2C8 | |
| SCHEMBL2652185 | 0.77 | GCGR (0.60) | GCGRCYP3A4CYP2C8CYP2C9GIPR | |
| SCHEMBL7116449 | 0.76 | GCGR (0.50) | GCGRIDH1EGLN1GIPR | |
| SCHEMBL2653452 | 0.76 | RIPK2 (0.45) | PTGER4PIN1NPC1 | |
| SCHEMBL9246297 | 0.76 | PTGER4 (0.58) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | PTGER4 412/4885GCGR 2/4885PIN1 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.